For instance, EGFR mutations compared to wt EGFR in NSCLC are usually associated with improved treatment outcomes and a longer OS.[31] KRAS mutations in NSCLC are associated with poor outcomes in response to EGFR therapies.[31] In colorectal cancer, BRAF mutations are associated with a shorter survival.[13] Consensus regarding the impact of PIK3CA mutations is contradictory. This evidence concerns the gene EGFR and non-small cell lung carcinoma.